The protocol with metformin in the initiation of pharmacotherapy for type 2 diabetes was 41.5%, the metformin of monotherapy (11.2%), metformin in combination therapy with one hypoglycemic drug (33.2%), metformin in combination therapy with two other hypoglycemic drugs (9.3%).